Huxley Health Inc. Provides Corporate Update - Appoints Bruce Linton as Chairman
January 30, 2024 08:30 ET
|
Huxley Health Inc
Huxley Health Inc. provides corporate update including groundbreaking IP filings and appointment of Mr. Bruce Linton as Chairman.
PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada
January 25, 2024 12:09 ET
|
PharmAla Biotech
PharmAla granted a Health Canada Controlled Drugs and Substances Dealer's License
Psychedelic Drugs Market Forecast to Reach $6.4 Billion by 2034: Psilocybin and Ketamine Therapies Gain Traction, Driving the Market at 12.17% CAGR
January 24, 2024 14:26 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Psychedelic Drugs Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. With the global...
Psychedelic Drugs Market to Surge to USD 4.6 Billion by 2030, Driven by Therapeutic Potential and Rising Mental Health Awareness
January 24, 2024 10:59 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Psychedelic Drugs Market 2030 by Source, Drug Type, Distribution Channel and Region - Partner & Customer Ecosystem Competitive Index &...
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
January 24, 2024 09:35 ET
|
PharmAla Biotech
PharmAla recieved a new OTCQB ticker, MDXXF.
Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
January 19, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Health granted amendment to its Health Canada Controlled Drugs and Substances Licence.
MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement
January 16, 2024 16:27 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
To date, MAPS has supported nearly 70 organizations worldwide to advance charitable projects in the psychedelic movementCurrently, MAPS serves as a fiscal sponsor for 10 organizations in the newly...
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
January 08, 2024 08:55 ET
|
PharmAla Biotech
PharmAla announces that its novel P1 molecule has been accepted by USPTO to its accelerated "Patent Prosecution Highway"
Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats
January 03, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Health Granted Precursor Licence for 3,4-Methylenedioxyphenyl-2-propanone (“MDP2P”), the precursor used in the chemical synthesis of MDMA.
PharmAla Files Audited Financials for Year Ending August 31, 2023
December 29, 2023 16:00 ET
|
PharmAla Biotech
PharmAla releases audited year-end financials for the period ended August 31st.